PTC Therapeutics, Inc. (PTCT) 10-Year Financial Performance & Capital Metrics

PTCT • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Show more

Revenue $807M -14.0%
EBITDA -$227M -11.8%
Net Income -$363M +42.0%
EPS (Diluted) -4.73 +43.5%
Gross Margin 92.89% -0.1%
EBITDA Margin -28.13% -30.0%
Operating Margin -37.5% +20.0%
Net Margin -45.03% +32.6%
ROE -
ROIC -32.19% +19.4%
Debt/Equity -
Interest Coverage -1.81 +46.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)
✓Strong 5Y sales CAGR of 21.3%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y42.75%

5Y21.32%

3Y14.42%

TTM97.54%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM265.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM244.11%

ROCE

10Y Avg-30.56%

5Y Avg-28.01%

3Y Avg-30.58%

Latest-25.04%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	36.77M	82.7M	194.39M	264.73M	306.98M	380.77M	538.59M	698.8M	937.82M	806.78M
Revenue Growth %	0.6%	1.25%	1.35%	0.36%	0.16%	0.24%	0.41%	0.3%	0.34%	-0.14%
Cost of Goods Sold+	121.82M	117.63M	4.58M	12.67M	12.13M	18.94M	32.33M	44.68M	65.49M	57.4M
COGS % of Revenue	3.31%	1.42%	0.02%	0.05%	0.04%	0.05%	0.06%	0.06%	0.07%	0.07%
Gross Profit+	-85.05M	-34.93M	189.81M	252.06M	294.85M	361.82M	506.26M	654.12M	872.34M	749.38M
Gross Margin %	-2.31%	-0.42%	0.98%	0.95%	0.96%	0.95%	0.94%	0.94%	0.93%	0.93%
Gross Profit Growth %	-0.5%	0.59%	6.43%	0.33%	0.17%	0.23%	0.4%	0.29%	0.33%	-0.14%
Operating Expenses+	203.9M	214.76M	254.11M	348.41M	536M	793.59M	880.71M	1.1B	1.31B	1.05B
OpEx % of Revenue	5.55%	2.6%	1.31%	1.32%	1.75%	2.08%	1.64%	1.58%	1.4%	1.3%
Selling, General & Admin	82.08M	97.13M	121.27M	153.55M	202.54M	245.16M	285.77M	326M	332.54M	300.91M
SG&A % of Revenue	2.23%	1.17%	0.62%	0.58%	0.66%	0.64%	0.53%	0.47%	0.35%	0.37%
Research & Development	121.82M	117.63M	117.46M	171.98M	257.45M	477.64M	540.68M	651.5M	666.56M	534.48M
R&D % of Revenue	3.31%	1.42%	0.6%	0.65%	0.84%	1.25%	1%	0.93%	0.71%	0.66%
Other Operating Expenses	-465K	-1.21M	-1.28M	129K	76.01M	70.78M	54.25M	124.04M	312.74M	216.56M
Operating Income+	-167.13M	-132.06M	-64.29M	-115.69M	-241.16M	-431.77M	-374.44M	-447.41M	-439.5M	-302.57M
Operating Margin %	-4.55%	-1.6%	-0.33%	-0.44%	-0.79%	-1.13%	-0.7%	-0.64%	-0.47%	-0.38%
Operating Income Growth %	-0.68%	0.21%	0.51%	-0.8%	-1.08%	-0.79%	0.13%	-0.19%	0.02%	0.31%
EBITDA+	-164.25M	-128.77M	-46.61M	-89.6M	-208.98M	-388.28M	-310.31M	-318.57M	-202.91M	-226.91M
EBITDA Margin %	-4.47%	-1.56%	-0.24%	-0.34%	-0.68%	-1.02%	-0.58%	-0.46%	-0.22%	-0.28%
EBITDA Growth %	-0.69%	0.22%	0.64%	-0.92%	-1.33%	-0.86%	0.2%	-0.03%	0.36%	-0.12%
D&A (Non-Cash Add-back)	2.88M	3.29M	17.68M	26.09M	32.18M	43.49M	64.13M	128.84M	236.59M	75.66M
EBIT	-167.13M	-132.06M	-64.29M	-115.56M	-227.44M	-346.58M	-432.32M	-496.62M	-566.93M	-196.13M
Net Interest Income+	-2.37M	-8.28M	-12.09M	-12.55M	-12.49M	-56.35M	-86.02M	-90.87M	-129.18M	-166.99M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	2.37M	8.28M	12.09M	12.55M	12.49M	56.35M	86.02M	90.87M	129.18M	166.99M
Other Income/Expense	-2.83M	-9.48M	-13.37M	-12.43M	1.23M	28.84M	-143.9M	-140.08M	-256.61M	-60.55M
Pretax Income+	-169.96M	-141.54M	-77.67M	-128.11M	-239.93M	-402.93M	-518.34M	-587.49M	-696.11M	-363.12M
Pretax Margin %	-4.62%	-1.71%	-0.4%	-0.48%	-0.78%	-1.06%	-0.96%	-0.84%	-0.74%	-0.45%
Income Tax+	485K	569K	1.33M	-29K	11.65M	35.23M	5.56M	-28.47M	-69.51M	176K
Effective Tax Rate %	1%	1%	1.02%	1%	1.05%	1.09%	1.01%	0.95%	0.9%	1%
Net Income+	-170.45M	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M
Net Margin %	-4.64%	-1.72%	-0.41%	-0.48%	-0.82%	-1.15%	-0.97%	-0.8%	-0.67%	-0.45%
Net Income Growth %	-0.82%	0.17%	0.44%	-0.62%	-0.96%	-0.74%	-0.2%	-0.07%	-0.12%	0.42%
Net Income (Continuing)	-170.45M	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.07	-4.17	-2.02	-2.75	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73
EPS Growth %	-0.71%	0.18%	0.52%	-0.36%	-0.55%	-0.56%	-0.12%	-0.05%	-0.07%	0.43%
EPS (Basic)	-5.07	-4.17	-2.02	-2.75	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73
Diluted Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M
Basic Shares Outstanding	33.62M	34.04M	39.11M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	355.95M	261.29M	249.06M	320.86M	779.28M	1.23B	954.37M	693.78M	1.22B	1.37B
Cash & Short-Term Investments	338.93M	231.67M	191.25M	227.59M	686.56M	1.1B	773.38M	410.7M	876.74M	1.14B
Cash Only	338.93M	231.67M	191.25M	227.59M	288.03M	208.81M	189.72M	279.83M	594M	779.71M
Short-Term Investments	0	0	0	0	398.54M	894.84M	583.66M	130.87M	282.74M	359.99M
Accounts Receivable	11.09M	24.93M	40.39M	67.91M	55.54M	69.93M	110.45M	155.61M	160.82M	158.55M
Days Sales Outstanding	110.14	110.02	75.85	93.63	66.03	67.03	74.85	81.28	62.59	71.73
Inventory	0	0	10.75M	16.12M	19.29M	18.7M	15.86M	21.81M	30.58M	23.19M
Days Inventory Outstanding	-	-	857.59	464.3	580.06	360.28	179.02	178.16	170.43	147.49
Other Current Assets	5.93M	4.69M	6.67M	9.25M	0	0	0	105.66M	150.49M	44.09M
Total Non-Current Assets+	12.09M	8.06M	142.59M	798.37M	844.5M	976.53M	983.69M	1.01B	677.07M	339.49M
Property, Plant & Equipment	8.97M	7.43M	8.38M	12.69M	35.24M	118.24M	130.01M	175.02M	178.99M	117.66M
Fixed Asset Turnover	4.10x	11.13x	23.21x	20.86x	8.71x	3.22x	4.14x	3.99x	5.24x	6.86x
Goodwill	0	0	0	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M
Intangible Assets	0	0	132.99M	701.03M	710.5M	715.33M	724.84M	705.89M	379.5M	118.79M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	3.12M	630K	1.22M	2.3M	16.41M	60.62M	46.5M	48.58M	36.25M	20.7M
Total Assets+	368.04M	269.35M	391.65M	1.12B	1.62B	2.21B	1.94B	1.71B	1.9B	1.71B
Asset Turnover	0.10x	0.31x	0.50x	0.24x	0.19x	0.17x	0.28x	0.41x	0.49x	0.47x
Asset Growth %	0.1%	-0.27%	0.45%	1.86%	0.45%	0.36%	-0.12%	-0.12%	0.11%	-0.1%
Total Current Liabilities+	45.39M	49.62M	82.05M	166.8M	235.86M	277.33M	509.35M	406.24M	603.1M	580.98M
Accounts Payable	5.78M	6.3M	15.28M	6M	10.32M	18.66M	23.03M	27.27M	6.04M	17.27M
Days Payables Outstanding	17.32	19.54	1.22K	172.88	310.53	359.66	260.05	222.77	33.69	109.85
Short-Term Debt	0	0	0	11.67M	20M	0	208.83M	72.15M	194.31M	257.82M
Deferred Revenue (Current)	139K	1000K	1000K	1000K	1000K	1000K	0	1000K	801K	1000K
Other Current Liabilities	26.84M	29.68M	45.12M	117.78M	120.16M	129.89M	118.86M	126.46M	139.82M	120.22M
Current Ratio	7.84x	5.27x	3.04x	1.92x	3.30x	4.44x	1.87x	1.71x	2.02x	2.35x
Quick Ratio	7.84x	5.27x	2.90x	1.83x	3.22x	4.37x	1.84x	1.65x	1.97x	2.31x
Cash Conversion Cycle	-	-	-285.25	385.05	335.57	67.65	-6.18	36.67	199.33	109.38
Total Non-Current Liabilities+	96.65M	100.14M	153.17M	601.7M	793.6M	1.45B	1.43B	1.65B	2.11B	2.22B
Long-Term Debt	91.85M	98.22M	144.97M	141.35M	293.86M	309.14M	956.59M	1.26B	1.9B	2.11B
Capital Lease Obligations	0	0	0	0	9.02M	102.55M	93.67M	119.53M	114.81M	90.52M
Deferred Tax Liabilities	-139K	0	-3.94M	122.03M	130.86M	136.74M	137.11M	102.83M	55.91M	0
Other Non-Current Liabilities	2.05M	335K	243K	328.6M	356.44M	900.53M	239.9M	166.64M	36.44M	22.23M
Total Liabilities	69.57M	149.76M	235.22M	768.5M	1.03B	1.73B	1.94B	2.05B	2.71B	2.8B
Total Debt+	94.61M	98.22M	144.97M	153.01M	328.03M	420.44M	1.27B	1.46B	2.23B	2.47B
Net Debt	-244.32M	-133.45M	-46.27M	-74.57M	40M	211.63M	1.08B	1.18B	1.64B	1.69B
Debt / Equity	0.32x	0.82x	0.93x	0.44x	0.55x	0.87x	882.73x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-70.61x	-15.96x	-5.32x	-9.21x	-19.31x	-7.66x	-4.35x	-4.92x	-3.40x	-1.81x
Total Equity+	298.47M	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.1B
Equity Growth %	0%	-0.6%	0.31%	1.24%	0.69%	-0.19%	-1%	-242.37%	-1.36%	-0.34%
Book Value per Share	8.88	3.51	3.99	7.53	10.10	7.30	0.02	-4.84	-10.94	-14.29
Total Shareholders' Equity	298.47M	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.1B
Common Stock	34K	34K	42K	51K	62K	70K	71K	72K	75K	77K
Retained Earnings	-593M	-735.11M	-814.11M	-938.92M	-1.19B	-1.63B	-2.1B	-2.66B	-3.28B	-3.65B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.2M	-1.49M	3.97M	1.46M	-10.58M	-60.96M	-24.28M	4.8M	-1.28M	-25.89M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-124.34M	-103.57M	-10.06M	-27.64M	-98.64M	-194.07M	-251.33M	-356.65M	-158.42M	-107.69M
Operating CF Margin %	-3.38%	-1.25%	-0.05%	-0.1%	-0.32%	-0.51%	-0.47%	-0.51%	-0.17%	-0.13%
Operating CF Growth %	-1.17%	0.17%	0.9%	-1.75%	-2.57%	-0.97%	-0.3%	-0.42%	0.56%	0.32%
Net Income	-170.45M	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M
Depreciation & Amortization	2.88M	3.29M	17.68M	26.09M	32.18M	84.87M	64.13M	128.84M	236.59M	75.66M
Stock-Based Compensation	33.98M	35.01M	30.56M	33.25M	42.13M	70.33M	103.51M	110.33M	131.21M	74.61M
Deferred Taxes	2.3M	-199K	199K	-490K	8.83M	5.87M	377K	-34.28M	-46.93M	-55.91M
Other Non-Cash Items	2.25M	9.41M	7.27M	27.38M	49.37M	46.11M	128.33M	82.81M	151.32M	58.7M
Working Capital Changes	4.7M	-8.96M	13.23M	14.21M	20.43M	36.91M	-23.79M	-85.33M	-4M	102.54M
Change in Receivables	-6.91M	-14.84M	-12.2M	-29.59M	11.53M	-10.48M	-44.99M	-48.47M	-1.54M	1.73M
Change in Inventory	-1.98M	893K	-6.45M	-5.82M	-3.46M	1.84M	1.8M	-6.67M	-8.18M	6.16M
Change in Payables	16.98M	4.26M	24.01M	43.11M	13.75M	53.59M	23.41M	27.54M	0	0
Cash from Investing+	-20.81M	104.48M	13.12M	-42.61M	-387.24M	-561.55M	219.18M	290.18M	-176.74M	44.18M
Capital Expenditures	-2.72M	-1.78M	-3.1M	-15.53M	-45.44M	-55.98M	-85.33M	-152.46M	-28.44M	-6.5M
CapEx % of Revenue	0.07%	0.02%	0.02%	0.06%	0.15%	0.15%	0.16%	0.22%	0.03%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-18.09M	106.26M	16.22M	13.38M	0	-38.13M	-57.12M	-128.44M	-92.18M	110.31M
Cash from Financing+	154.06M	968K	44.22M	131.57M	613.21M	668.72M	20.88M	167.95M	646.4M	255.87M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.06M	968K	4.22M	13.65M	21.85M	686.78M	0	-30.77M	947.78M	257.36M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-127.06M	-105.34M	-13.16M	-43.17M	-144.08M	-250.05M	-336.66M	-509.11M	-279.04M	-181.94M
FCF Margin %	-3.46%	-1.27%	-0.07%	-0.16%	-0.47%	-0.66%	-0.63%	-0.73%	-0.3%	-0.23%
FCF Growth %	-1.05%	0.17%	0.88%	-2.28%	-2.34%	-0.74%	-0.35%	-0.51%	0.45%	0.35%
FCF per Share	-3.78	-3.09	-0.34	-0.93	-2.45	-3.79	-4.78	-7.10	-3.73	-2.37
FCF Conversion (FCF/Net Income)	0.73x	0.73x	0.13x	0.22x	0.39x	0.44x	0.48x	0.64x	0.25x	0.30x
Interest Paid	0	4.51M	6.27M	7.77M	7.69M	9.8M	9.59M	18.46M	36.13M	5.82M
Taxes Paid	111K	943K	1.1M	1.58M	2.11M	26.4M	7.71M	4.92M	14.15M	17.55M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-57.11%	-67.99%	-57.24%	-50.51%	-53.24%	-81.42%	-216.75%	-	-	-
Return on Invested Capital (ROIC)	-670.74%	-491.74%	-100.15%	-44.92%	-39.73%	-48.77%	-31.65%	-35.03%	-39.93%	-32.19%
Gross Margin	-231.33%	-42.23%	97.65%	95.21%	96.05%	95.03%	94%	93.61%	93.02%	92.89%
Net Margin	-463.6%	-171.83%	-40.64%	-48.38%	-81.95%	-115.07%	-97.27%	-80%	-66.81%	-45.03%
Debt / Equity	0.32x	0.82x	0.93x	0.44x	0.55x	0.87x	882.73x	-	-	-
Interest Coverage	-70.61x	-15.96x	-5.32x	-9.21x	-19.31x	-7.66x	-4.35x	-4.92x	-3.40x	-1.81x
FCF Conversion	0.73x	0.73x	0.13x	0.22x	0.39x	0.44x	0.48x	0.64x	0.25x	0.30x
Revenue Growth	60.11%	124.95%	135.04%	36.19%	15.96%	24.04%	41.45%	29.75%	34.2%	-13.97%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	291.31M	-	-	-	-	600.95M
Product Growth	-	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-	-	-	203.86M
Royalty Growth	-	-	-	-	-	-	-	-	-	-
Manufacturing	-	-	-	-	-	-	-	-	7.69M	1.66M
Manufacturing Growth	-	-	-	-	-	-	-	-	-	-78.39%
Collaboration Revenue	-	-	-	-	-	-	-	-	100.03M	304K
Collaboration Revenue Growth	-	-	-	-	-	-	-	-	-	-99.70%
Grant And Collaboration	-	-	-	-	15.67M	-	-	-	-	-
Grant And Collaboration Growth	-	-	-	-	-	-	-	-	-	-
Early Stage Collaborations	-	-	-	252M	-	-	-	-	-	-
Early Stage Collaborations Growth	-	-	-	-	-	-	-	-	-	-
Translarna	-	-	145.2M	171M	-	-	-	-	-	-
Translarna Growth	-	-	-	17.77%	-	-	-	-	-	-
Emflaza	-	-	28.8M	92M	-	-	-	-	-	-
Emflaza Growth	-	-	-	219.44%	-	-	-	-	-	-
Licensing And Collaboration Agreement	-	-	-	200K	-	-	-	-	-	-
Licensing And Collaboration Agreement Growth	-	-	-	-	-	-	-	-	-	-
Grant	-	-	-	-	-	-	-	-	-	-
Grant Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
United States	-	-	-	-	-	-	187.3M	218.3M	531.66M	413.04M
United States Growth	-	-	-	-	-	-	-	16.55%	143.55%	-22.31%
Non-US	-	81.5M	145.24M	171.04M	190.3M	-	236M	288.6M	406.16M	393.8M
Non-US Growth	-	-	78.21%	17.77%	11.26%	-	-	22.29%	40.73%	-3.04%
Non Us	31.55M	-	-	-	-	194.4M	-	-	-	-
Non Us Growth	-	-	-	-	-	-	-	-	-	-
U	5.22M	-	-	-	-	139M	-	-	-	-
U Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	1.21M	49.16M	93.69M	116.68M	-	-	-	-	-
UNITED STATES Growth	-	-	3975.87%	90.61%	24.53%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

PTC Therapeutics, Inc. (PTCT) reported $1.78B in revenue for fiscal year 2024. This represents a 1698% increase from $99.0M in 2011.

PTC Therapeutics, Inc. (PTCT) saw revenue decline by 14.0% over the past year.

Yes, PTC Therapeutics, Inc. (PTCT) is profitable, generating $751.7M in net income for fiscal year 2024 (-45.0% net margin).

Dividend & Returns

PTC Therapeutics, Inc. (PTCT) generated $699.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

PTC Therapeutics, Inc. (PTCT) 10-Year Financial Performance & Capital Metrics

PTCT • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $807M -14.0%
EBITDA -$227M -11.8%
Net Income -$363M +42.0%
EPS (Diluted) -4.73 +43.5%
Gross Margin 92.89% -0.1%
EBITDA Margin -28.13% -30.0%
Operating Margin -37.5% +20.0%
Net Margin -45.03% +32.6%
ROE -
ROIC -32.19% +19.4%
Debt/Equity -
Interest Coverage -1.81 +46.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)
✓Strong 5Y sales CAGR of 21.3%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y42.75%

5Y21.32%

3Y14.42%

TTM97.54%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM265.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM244.11%

ROCE

10Y Avg-30.56%

5Y Avg-28.01%

3Y Avg-30.58%

Latest-25.04%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	36.77M	82.7M	194.39M	264.73M	306.98M	380.77M	538.59M	698.8M	937.82M	806.78M
Revenue Growth %	0.6%	1.25%	1.35%	0.36%	0.16%	0.24%	0.41%	0.3%	0.34%	-0.14%
Cost of Goods Sold+	121.82M	117.63M	4.58M	12.67M	12.13M	18.94M	32.33M	44.68M	65.49M	57.4M
COGS % of Revenue	3.31%	1.42%	0.02%	0.05%	0.04%	0.05%	0.06%	0.06%	0.07%	0.07%
Gross Profit+	-85.05M	-34.93M	189.81M	252.06M	294.85M	361.82M	506.26M	654.12M	872.34M	749.38M
Gross Margin %	-2.31%	-0.42%	0.98%	0.95%	0.96%	0.95%	0.94%	0.94%	0.93%	0.93%
Gross Profit Growth %	-0.5%	0.59%	6.43%	0.33%	0.17%	0.23%	0.4%	0.29%	0.33%	-0.14%
Operating Expenses+	203.9M	214.76M	254.11M	348.41M	536M	793.59M	880.71M	1.1B	1.31B	1.05B
OpEx % of Revenue	5.55%	2.6%	1.31%	1.32%	1.75%	2.08%	1.64%	1.58%	1.4%	1.3%
Selling, General & Admin	82.08M	97.13M	121.27M	153.55M	202.54M	245.16M	285.77M	326M	332.54M	300.91M
SG&A % of Revenue	2.23%	1.17%	0.62%	0.58%	0.66%	0.64%	0.53%	0.47%	0.35%	0.37%
Research & Development	121.82M	117.63M	117.46M	171.98M	257.45M	477.64M	540.68M	651.5M	666.56M	534.48M
R&D % of Revenue	3.31%	1.42%	0.6%	0.65%	0.84%	1.25%	1%	0.93%	0.71%	0.66%
Other Operating Expenses	-465K	-1.21M	-1.28M	129K	76.01M	70.78M	54.25M	124.04M	312.74M	216.56M
Operating Income+	-167.13M	-132.06M	-64.29M	-115.69M	-241.16M	-431.77M	-374.44M	-447.41M	-439.5M	-302.57M
Operating Margin %	-4.55%	-1.6%	-0.33%	-0.44%	-0.79%	-1.13%	-0.7%	-0.64%	-0.47%	-0.38%
Operating Income Growth %	-0.68%	0.21%	0.51%	-0.8%	-1.08%	-0.79%	0.13%	-0.19%	0.02%	0.31%
EBITDA+	-164.25M	-128.77M	-46.61M	-89.6M	-208.98M	-388.28M	-310.31M	-318.57M	-202.91M	-226.91M
EBITDA Margin %	-4.47%	-1.56%	-0.24%	-0.34%	-0.68%	-1.02%	-0.58%	-0.46%	-0.22%	-0.28%
EBITDA Growth %	-0.69%	0.22%	0.64%	-0.92%	-1.33%	-0.86%	0.2%	-0.03%	0.36%	-0.12%
D&A (Non-Cash Add-back)	2.88M	3.29M	17.68M	26.09M	32.18M	43.49M	64.13M	128.84M	236.59M	75.66M
EBIT	-167.13M	-132.06M	-64.29M	-115.56M	-227.44M	-346.58M	-432.32M	-496.62M	-566.93M	-196.13M
Net Interest Income+	-2.37M	-8.28M	-12.09M	-12.55M	-12.49M	-56.35M	-86.02M	-90.87M	-129.18M	-166.99M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	2.37M	8.28M	12.09M	12.55M	12.49M	56.35M	86.02M	90.87M	129.18M	166.99M
Other Income/Expense	-2.83M	-9.48M	-13.37M	-12.43M	1.23M	28.84M	-143.9M	-140.08M	-256.61M	-60.55M
Pretax Income+	-169.96M	-141.54M	-77.67M	-128.11M	-239.93M	-402.93M	-518.34M	-587.49M	-696.11M	-363.12M
Pretax Margin %	-4.62%	-1.71%	-0.4%	-0.48%	-0.78%	-1.06%	-0.96%	-0.84%	-0.74%	-0.45%
Income Tax+	485K	569K	1.33M	-29K	11.65M	35.23M	5.56M	-28.47M	-69.51M	176K
Effective Tax Rate %	1%	1%	1.02%	1%	1.05%	1.09%	1.01%	0.95%	0.9%	1%
Net Income+	-170.45M	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M
Net Margin %	-4.64%	-1.72%	-0.41%	-0.48%	-0.82%	-1.15%	-0.97%	-0.8%	-0.67%	-0.45%
Net Income Growth %	-0.82%	0.17%	0.44%	-0.62%	-0.96%	-0.74%	-0.2%	-0.07%	-0.12%	0.42%
Net Income (Continuing)	-170.45M	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.07	-4.17	-2.02	-2.75	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73
EPS Growth %	-0.71%	0.18%	0.52%	-0.36%	-0.55%	-0.56%	-0.12%	-0.05%	-0.07%	0.43%
EPS (Basic)	-5.07	-4.17	-2.02	-2.75	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73
Diluted Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M
Basic Shares Outstanding	33.62M	34.04M	39.11M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	355.95M	261.29M	249.06M	320.86M	779.28M	1.23B	954.37M	693.78M	1.22B	1.37B
Cash & Short-Term Investments	338.93M	231.67M	191.25M	227.59M	686.56M	1.1B	773.38M	410.7M	876.74M	1.14B
Cash Only	338.93M	231.67M	191.25M	227.59M	288.03M	208.81M	189.72M	279.83M	594M	779.71M
Short-Term Investments	0	0	0	0	398.54M	894.84M	583.66M	130.87M	282.74M	359.99M
Accounts Receivable	11.09M	24.93M	40.39M	67.91M	55.54M	69.93M	110.45M	155.61M	160.82M	158.55M
Days Sales Outstanding	110.14	110.02	75.85	93.63	66.03	67.03	74.85	81.28	62.59	71.73
Inventory	0	0	10.75M	16.12M	19.29M	18.7M	15.86M	21.81M	30.58M	23.19M
Days Inventory Outstanding	-	-	857.59	464.3	580.06	360.28	179.02	178.16	170.43	147.49
Other Current Assets	5.93M	4.69M	6.67M	9.25M	0	0	0	105.66M	150.49M	44.09M
Total Non-Current Assets+	12.09M	8.06M	142.59M	798.37M	844.5M	976.53M	983.69M	1.01B	677.07M	339.49M
Property, Plant & Equipment	8.97M	7.43M	8.38M	12.69M	35.24M	118.24M	130.01M	175.02M	178.99M	117.66M
Fixed Asset Turnover	4.10x	11.13x	23.21x	20.86x	8.71x	3.22x	4.14x	3.99x	5.24x	6.86x
Goodwill	0	0	0	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M
Intangible Assets	0	0	132.99M	701.03M	710.5M	715.33M	724.84M	705.89M	379.5M	118.79M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	3.12M	630K	1.22M	2.3M	16.41M	60.62M	46.5M	48.58M	36.25M	20.7M
Total Assets+	368.04M	269.35M	391.65M	1.12B	1.62B	2.21B	1.94B	1.71B	1.9B	1.71B
Asset Turnover	0.10x	0.31x	0.50x	0.24x	0.19x	0.17x	0.28x	0.41x	0.49x	0.47x
Asset Growth %	0.1%	-0.27%	0.45%	1.86%	0.45%	0.36%	-0.12%	-0.12%	0.11%	-0.1%
Total Current Liabilities+	45.39M	49.62M	82.05M	166.8M	235.86M	277.33M	509.35M	406.24M	603.1M	580.98M
Accounts Payable	5.78M	6.3M	15.28M	6M	10.32M	18.66M	23.03M	27.27M	6.04M	17.27M
Days Payables Outstanding	17.32	19.54	1.22K	172.88	310.53	359.66	260.05	222.77	33.69	109.85
Short-Term Debt	0	0	0	11.67M	20M	0	208.83M	72.15M	194.31M	257.82M
Deferred Revenue (Current)	139K	1000K	1000K	1000K	1000K	1000K	0	1000K	801K	1000K
Other Current Liabilities	26.84M	29.68M	45.12M	117.78M	120.16M	129.89M	118.86M	126.46M	139.82M	120.22M
Current Ratio	7.84x	5.27x	3.04x	1.92x	3.30x	4.44x	1.87x	1.71x	2.02x	2.35x
Quick Ratio	7.84x	5.27x	2.90x	1.83x	3.22x	4.37x	1.84x	1.65x	1.97x	2.31x
Cash Conversion Cycle	-	-	-285.25	385.05	335.57	67.65	-6.18	36.67	199.33	109.38
Total Non-Current Liabilities+	96.65M	100.14M	153.17M	601.7M	793.6M	1.45B	1.43B	1.65B	2.11B	2.22B
Long-Term Debt	91.85M	98.22M	144.97M	141.35M	293.86M	309.14M	956.59M	1.26B	1.9B	2.11B
Capital Lease Obligations	0	0	0	0	9.02M	102.55M	93.67M	119.53M	114.81M	90.52M
Deferred Tax Liabilities	-139K	0	-3.94M	122.03M	130.86M	136.74M	137.11M	102.83M	55.91M	0
Other Non-Current Liabilities	2.05M	335K	243K	328.6M	356.44M	900.53M	239.9M	166.64M	36.44M	22.23M
Total Liabilities	69.57M	149.76M	235.22M	768.5M	1.03B	1.73B	1.94B	2.05B	2.71B	2.8B
Total Debt+	94.61M	98.22M	144.97M	153.01M	328.03M	420.44M	1.27B	1.46B	2.23B	2.47B
Net Debt	-244.32M	-133.45M	-46.27M	-74.57M	40M	211.63M	1.08B	1.18B	1.64B	1.69B
Debt / Equity	0.32x	0.82x	0.93x	0.44x	0.55x	0.87x	882.73x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-70.61x	-15.96x	-5.32x	-9.21x	-19.31x	-7.66x	-4.35x	-4.92x	-3.40x	-1.81x
Total Equity+	298.47M	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.1B
Equity Growth %	0%	-0.6%	0.31%	1.24%	0.69%	-0.19%	-1%	-242.37%	-1.36%	-0.34%
Book Value per Share	8.88	3.51	3.99	7.53	10.10	7.30	0.02	-4.84	-10.94	-14.29
Total Shareholders' Equity	298.47M	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.1B
Common Stock	34K	34K	42K	51K	62K	70K	71K	72K	75K	77K
Retained Earnings	-593M	-735.11M	-814.11M	-938.92M	-1.19B	-1.63B	-2.1B	-2.66B	-3.28B	-3.65B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.2M	-1.49M	3.97M	1.46M	-10.58M	-60.96M	-24.28M	4.8M	-1.28M	-25.89M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-124.34M	-103.57M	-10.06M	-27.64M	-98.64M	-194.07M	-251.33M	-356.65M	-158.42M	-107.69M
Operating CF Margin %	-3.38%	-1.25%	-0.05%	-0.1%	-0.32%	-0.51%	-0.47%	-0.51%	-0.17%	-0.13%
Operating CF Growth %	-1.17%	0.17%	0.9%	-1.75%	-2.57%	-0.97%	-0.3%	-0.42%	0.56%	0.32%
Net Income	-170.45M	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M
Depreciation & Amortization	2.88M	3.29M	17.68M	26.09M	32.18M	84.87M	64.13M	128.84M	236.59M	75.66M
Stock-Based Compensation	33.98M	35.01M	30.56M	33.25M	42.13M	70.33M	103.51M	110.33M	131.21M	74.61M
Deferred Taxes	2.3M	-199K	199K	-490K	8.83M	5.87M	377K	-34.28M	-46.93M	-55.91M
Other Non-Cash Items	2.25M	9.41M	7.27M	27.38M	49.37M	46.11M	128.33M	82.81M	151.32M	58.7M
Working Capital Changes	4.7M	-8.96M	13.23M	14.21M	20.43M	36.91M	-23.79M	-85.33M	-4M	102.54M
Change in Receivables	-6.91M	-14.84M	-12.2M	-29.59M	11.53M	-10.48M	-44.99M	-48.47M	-1.54M	1.73M
Change in Inventory	-1.98M	893K	-6.45M	-5.82M	-3.46M	1.84M	1.8M	-6.67M	-8.18M	6.16M
Change in Payables	16.98M	4.26M	24.01M	43.11M	13.75M	53.59M	23.41M	27.54M	0	0
Cash from Investing+	-20.81M	104.48M	13.12M	-42.61M	-387.24M	-561.55M	219.18M	290.18M	-176.74M	44.18M
Capital Expenditures	-2.72M	-1.78M	-3.1M	-15.53M	-45.44M	-55.98M	-85.33M	-152.46M	-28.44M	-6.5M
CapEx % of Revenue	0.07%	0.02%	0.02%	0.06%	0.15%	0.15%	0.16%	0.22%	0.03%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-18.09M	106.26M	16.22M	13.38M	0	-38.13M	-57.12M	-128.44M	-92.18M	110.31M
Cash from Financing+	154.06M	968K	44.22M	131.57M	613.21M	668.72M	20.88M	167.95M	646.4M	255.87M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.06M	968K	4.22M	13.65M	21.85M	686.78M	0	-30.77M	947.78M	257.36M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-127.06M	-105.34M	-13.16M	-43.17M	-144.08M	-250.05M	-336.66M	-509.11M	-279.04M	-181.94M
FCF Margin %	-3.46%	-1.27%	-0.07%	-0.16%	-0.47%	-0.66%	-0.63%	-0.73%	-0.3%	-0.23%
FCF Growth %	-1.05%	0.17%	0.88%	-2.28%	-2.34%	-0.74%	-0.35%	-0.51%	0.45%	0.35%
FCF per Share	-3.78	-3.09	-0.34	-0.93	-2.45	-3.79	-4.78	-7.10	-3.73	-2.37
FCF Conversion (FCF/Net Income)	0.73x	0.73x	0.13x	0.22x	0.39x	0.44x	0.48x	0.64x	0.25x	0.30x
Interest Paid	0	4.51M	6.27M	7.77M	7.69M	9.8M	9.59M	18.46M	36.13M	5.82M
Taxes Paid	111K	943K	1.1M	1.58M	2.11M	26.4M	7.71M	4.92M	14.15M	17.55M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-57.11%	-67.99%	-57.24%	-50.51%	-53.24%	-81.42%	-216.75%	-	-	-
Return on Invested Capital (ROIC)	-670.74%	-491.74%	-100.15%	-44.92%	-39.73%	-48.77%	-31.65%	-35.03%	-39.93%	-32.19%
Gross Margin	-231.33%	-42.23%	97.65%	95.21%	96.05%	95.03%	94%	93.61%	93.02%	92.89%
Net Margin	-463.6%	-171.83%	-40.64%	-48.38%	-81.95%	-115.07%	-97.27%	-80%	-66.81%	-45.03%
Debt / Equity	0.32x	0.82x	0.93x	0.44x	0.55x	0.87x	882.73x	-	-	-
Interest Coverage	-70.61x	-15.96x	-5.32x	-9.21x	-19.31x	-7.66x	-4.35x	-4.92x	-3.40x	-1.81x
FCF Conversion	0.73x	0.73x	0.13x	0.22x	0.39x	0.44x	0.48x	0.64x	0.25x	0.30x
Revenue Growth	60.11%	124.95%	135.04%	36.19%	15.96%	24.04%	41.45%	29.75%	34.2%	-13.97%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	291.31M	-	-	-	-	600.95M
Product Growth	-	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-	-	-	203.86M
Royalty Growth	-	-	-	-	-	-	-	-	-	-
Manufacturing	-	-	-	-	-	-	-	-	7.69M	1.66M
Manufacturing Growth	-	-	-	-	-	-	-	-	-	-78.39%
Collaboration Revenue	-	-	-	-	-	-	-	-	100.03M	304K
Collaboration Revenue Growth	-	-	-	-	-	-	-	-	-	-99.70%
Grant And Collaboration	-	-	-	-	15.67M	-	-	-	-	-
Grant And Collaboration Growth	-	-	-	-	-	-	-	-	-	-
Early Stage Collaborations	-	-	-	252M	-	-	-	-	-	-
Early Stage Collaborations Growth	-	-	-	-	-	-	-	-	-	-
Translarna	-	-	145.2M	171M	-	-	-	-	-	-
Translarna Growth	-	-	-	17.77%	-	-	-	-	-	-
Emflaza	-	-	28.8M	92M	-	-	-	-	-	-
Emflaza Growth	-	-	-	219.44%	-	-	-	-	-	-
Licensing And Collaboration Agreement	-	-	-	200K	-	-	-	-	-	-
Licensing And Collaboration Agreement Growth	-	-	-	-	-	-	-	-	-	-
Grant	-	-	-	-	-	-	-	-	-	-
Grant Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
United States	-	-	-	-	-	-	187.3M	218.3M	531.66M	413.04M
United States Growth	-	-	-	-	-	-	-	16.55%	143.55%	-22.31%
Non-US	-	81.5M	145.24M	171.04M	190.3M	-	236M	288.6M	406.16M	393.8M
Non-US Growth	-	-	78.21%	17.77%	11.26%	-	-	22.29%	40.73%	-3.04%
Non Us	31.55M	-	-	-	-	194.4M	-	-	-	-
Non Us Growth	-	-	-	-	-	-	-	-	-	-
U	5.22M	-	-	-	-	139M	-	-	-	-
U Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	1.21M	49.16M	93.69M	116.68M	-	-	-	-	-
UNITED STATES Growth	-	-	3975.87%	90.61%	24.53%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

PTC Therapeutics, Inc. (PTCT) reported $1.78B in revenue for fiscal year 2024. This represents a 1698% increase from $99.0M in 2011.

PTC Therapeutics, Inc. (PTCT) saw revenue decline by 14.0% over the past year.

Yes, PTC Therapeutics, Inc. (PTCT) is profitable, generating $751.7M in net income for fiscal year 2024 (-45.0% net margin).

Dividend & Returns

PTC Therapeutics, Inc. (PTCT) generated $699.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.